Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
What is the ticker symbol for Trevi Therapeutics Inc? What does TRVI stand for in stocks?
TRVI is the stock ticker symbol of Trevi Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Trevi Therapeutics Inc (TRVI)?
As of Tue Oct 29 2024, market cap of Trevi Therapeutics Inc is 222.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of TRVI stock?
You can check TRVI's fair value in chart for subscribers.
Is Trevi Therapeutics Inc a good stock to buy?
The fair value guage provides a quick view whether TRVI is over valued or under valued. Whether Trevi Therapeutics Inc is cheap or expensive depends on the assumptions which impact Trevi Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TRVI.